DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Steroids Added to Dithranol and Narrow Band UVB (UVBnb) in Psoriasis

Information source: University of Zurich
Information obtained from ClinicalTrials.gov on February 07, 2013
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Psoriasis

Intervention: Topical steroids (Drug)

Phase: Phase 4

Status: Recruiting

Sponsored by: University of Zurich

Official(s) and/or principal investigator(s):
Guenther Hofbauer, MD, Leading Physician, Principal Investigator, Affiliation: University Hospital Zurich, Division of Dermatology

Overall contact:
Guenther Hofbauer, MD, Email: hofbauer@usz.ch

Summary

Objective(s):

(i) To assess the effect of adjunctive topical steroids in the combined treatment with UVBnb and dithranol on the remission time after therapy till a relapse of psoriasis defined as 50% loss of PASI improvement obtained through the antecedent treatment.

(ii) To assess the impact of adjuvant topical steroids in the combined treatment with UVBnb and dithranol on the clearing time of psoriasis lesions under therapy (PASI 75).

- Trial with medicinal product

Clinical Details

Official title: DIPSO A Phase IV, Randomized, Double Blind, Placebo Controlled, Single-center Study of the Impact of Topical Steroids on Narrow Band UVB and Dithranol Combination Treatment of Psoriasis

Study design: Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Primary outcome: Relapse 50% PASI after treatment, time to PASI 75% on treatment

Detailed description: (i) To assess the effect of adjunctive topical steroids in the combined treatment with UVBnb and dithranol on the remission time after therapy till a relapse of psoriasis defined as 50% loss of PASI improvement obtained through the antecedent treatment.

(ii) To assess the impact of adjuvant topical steroids in the combined treatment with UVBnb and dithranol on the clearing time of psoriasis lesions under therapy (PASI 75).

- Trial with medicinal product

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion criteria:

- Moderate to severe psoriasis of the chronic-plaque and / or guttata type

Exclusion criteria:

- Participation in a Goeckerman therapy regimen within 6 months previous to the present

study

Locations and Contacts

Guenther Hofbauer, MD, Email: hofbauer@usz.ch

University Hospital Dermatology Department, Zurich 8091, Switzerland; Recruiting
Martin Glatz, MD, Phone: +41442551111, Email: martin.glatz@usz.ch
Additional Information

Starting date: August 2011
Last updated: January 28, 2013

Page last updated: February 07, 2013

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014